| Year |
Citation |
Score |
| 2020 |
Siderowf A, Jennings D, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32657461 DOI: 10.1002/Mds.28139 |
0.309 |
|
| 2019 |
Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I. The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study. Clinical Genetics. PMID 31093973 DOI: 10.1111/Cge.13529 |
0.302 |
|
| 2018 |
Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C. Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". Parkinsonism & Related Disorders. PMID 30655161 DOI: 10.1016/J.Parkreldis.2018.12.028 |
0.323 |
|
| 2018 |
Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW, Pyykkonen K, McNitt S, Oakes D, Feng C, Aktas MK, Ayala-Parades F, Baranchuk A, Dubuc M, Haigney M, et al. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. Journal of the American College of Cardiology. 72: 636-645. PMID 30071993 DOI: 10.1016/j.jacc.2018.04.086 |
0.383 |
|
| 2018 |
Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C. Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism & Related Disorders. PMID 30056038 DOI: 10.1016/J.Parkreldis.2018.07.009 |
0.315 |
|
| 2017 |
Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. PMID 28701493 DOI: 10.1212/Wnl.0000000000004209 |
0.304 |
|
| 2017 |
Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. Jama Neurology. PMID 28595287 DOI: 10.1001/Jamaneurol.2017.0985 |
0.335 |
|
| 2017 |
Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Annals of Clinical and Translational Neurology. 4: 360-368. PMID 28589163 DOI: 10.1002/Acn3.412 |
0.333 |
|
| 2016 |
Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I. Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice. 3: 53-58. PMID 30363507 DOI: 10.1002/Mdc3.12273 |
0.307 |
|
| 2015 |
Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. Jama Neurology. 1-9. PMID 26569098 DOI: 10.1001/Jamaneurol.2015.2736 |
0.301 |
|
| 2015 |
Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, ... ... Oakes D, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202 |
0.334 |
|
| 2015 |
Müller ML, Albin RL, Bohnen NI, Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study. Neurology. 84: 2292. PMID 26033339 DOI: 10.1212/Wnl.0000000000001654 |
0.304 |
|
| 2015 |
Ravina B, Eberly S, Oakes D, Lang AE, Dodelet V, Roos P, Harman J, Shoulson I, Schipper HM. Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. Biomarkers in Medicine. 9: 89-97. PMID 25689898 DOI: 10.2217/Bmm.14.103 |
0.308 |
|
| 2014 |
Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 83: 1739-46. PMID 25298306 DOI: 10.1212/Wnl.0000000000000960 |
0.327 |
|
| 2014 |
Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Annals of Neurology. 76: 862-8. PMID 25257975 DOI: 10.1002/Ana.24281 |
0.339 |
|
| 2014 |
Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 82: 1791-7. PMID 24759846 DOI: 10.1212/Wnl.0000000000000424 |
0.316 |
|
| 2014 |
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. Jama Neurology. 71: 543-52. PMID 24664227 DOI: 10.1001/Jamaneurol.2014.131 |
0.346 |
|
| 2014 |
Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, DiEuliis D, Fahn S, et al. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 743-9. PMID 24515275 DOI: 10.1002/Mds.25814 |
0.343 |
|
| 2014 |
Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528 |
0.351 |
|
| 2013 |
Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1980-6. PMID 24123383 DOI: 10.1002/Mds.25671 |
0.33 |
|
| 2013 |
Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology. 81: 1134-40. PMID 23966247 DOI: 10.1212/Wnl.0B013E3182A55Ede |
0.309 |
|
| 2013 |
Marras C, Oakes D. Author reply to Holford, Vu and Nutt regarding 'piecing together the puzzle of progression and mortality in Parkinson's disease' British Journal of Clinical Pharmacology. 75: 1372. PMID 22989073 DOI: 10.1111/J.1365-2125.2012.04464.X |
0.315 |
|
| 2012 |
Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1392-7. PMID 22976926 DOI: 10.1002/Mds.25157 |
0.33 |
|
| 2012 |
Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 880-7. PMID 22555881 DOI: 10.1002/Mds.24978 |
0.334 |
|
| 2012 |
Marras C, Oakes D. Piecing together the puzzle of progression and mortality in Parkinson's disease British Journal of Clinical Pharmacology. 74: 264-266. PMID 22554391 DOI: 10.1111/J.1365-2125.2012.04315.X |
0.391 |
|
| 2011 |
Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of parkinson's disease: Results from DATATOP Plos One. 6. PMID 21853051 DOI: 10.1371/Journal.Pone.0022854 |
0.316 |
|
| 2011 |
Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1864-8. PMID 21538532 DOI: 10.1002/Mds.23741 |
0.322 |
|
| 2010 |
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1801-8. PMID 20669311 DOI: 10.1002/Mds.23006 |
0.318 |
|
| 2010 |
Oakes D, Feng C. Combining stratified and unstratified log-rank tests in paired survival data Statistics in Medicine. 29: 1735-1745. PMID 20572124 DOI: 10.1002/Sim.3921 |
0.488 |
|
| 2009 |
Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 2370-8. PMID 19908310 DOI: 10.1002/Mds.22828 |
0.38 |
|
| 2009 |
Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 2328-36. PMID 19908302 DOI: 10.1002/Mds.22759 |
0.337 |
|
| 2009 |
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, ... Oakes D, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology. 66: 1460-8. PMID 19822770 DOI: 10.1001/Archneurol.2009.247 |
0.334 |
|
| 2009 |
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 2081-90. PMID 19691116 DOI: 10.1002/Mds.22690 |
0.338 |
|
| 2009 |
Simuni T, Biglan K, Oakes D, Gardiner N, Deeley C, Surmeier D. P2.161 STEADY-PD: safety, tolerability, and efflcacy assessment of isradipine (Dynacirc CR) in early Parkinson disease Parkinsonism & Related Disorders. 15: S133. DOI: 10.1016/S1353-8020(09)70512-7 |
0.302 |
|
| 2008 |
Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 71: 481-5. PMID 18695158 DOI: 10.1212/01.Wnl.0000324862.29733.69 |
0.345 |
|
| 2008 |
Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clinical Neuropharmacology. 31: 127-33. PMID 18520979 DOI: 10.1097/Wnf.0B013E3180Ca77Ea |
0.319 |
|
| 2008 |
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Archives of Neurology. 65: 716-23. PMID 18413464 DOI: 10.1001/Archneur.2008.65.6.Nct70003 |
0.348 |
|
| 2008 |
Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 874-80. PMID 18096682 DOI: 10.1136/Jnnp.2007.128728 |
0.319 |
|
| 2008 |
Wang A, Oakes D. Some properties of the Kendall distribution in bivariate Archimedean copula models under censoring Statistics and Probability Letters. 78: 2578-2583. DOI: 10.1016/J.Spl.2008.07.018 |
0.497 |
|
| 2006 |
Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Archives of Neurology. 63: 883-90. PMID 16769871 DOI: 10.1001/Archneur.63.6.883 |
0.344 |
|
| 2006 |
Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Annals of Neurology. 60: 65-72. PMID 16718702 DOI: 10.1002/Ana.20882 |
0.3 |
|
| 2006 |
Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Archives of Neurology. 63: 210-6. PMID 16476809 DOI: 10.1001/Archneur.63.2.210 |
0.345 |
|
| 2006 |
Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I. Rasagiline improves quality of life in patients with early Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 616-23. PMID 16450340 DOI: 10.1002/Mds.20764 |
0.319 |
|
| 2005 |
Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clinical Neuropharmacology. 28: 215-9. PMID 16239760 DOI: 10.1097/01.Wnf.0000180228.77802.32 |
0.33 |
|
| 2005 |
Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 293-7. PMID 15584032 DOI: 10.1002/Mds.20332 |
0.305 |
|
| 2004 |
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine. 351: 2498-508. PMID 15590952 DOI: 10.1056/Nejmoa033447 |
0.344 |
|
| 2003 |
Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease Experimental Neurology. 184. PMID 14597329 DOI: 10.1016/J.Expneurol.2003.08.008 |
0.309 |
|
| 2003 |
Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T. Reliability of reported age at onset for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 275-9. PMID 12621630 DOI: 10.1002/Mds.10391 |
0.309 |
|
| 2003 |
Oakes D, Wang A. Copula model generated by Dabrowska's association measure Biometrika. 90: 478-481. DOI: 10.1093/Biomet/90.2.478 |
0.495 |
|
| 2002 |
Siderowf A, Stern M, Shoulson I, Kieburtz K, Oakes D, Day D, Shinaman A, Plumb S, Fahn S, Blindauer K, Lew M, Hurtig H, Lloyd M, Hauser R, Gauger L, et al. A controlled trial of rasagiline in early Parkinson disease: The tempo study Archives of Neurology. 59: 1937-1943. PMID 12470183 DOI: 10.1001/Archneur.59.12.1937 |
0.367 |
|
| 2002 |
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 59: 1541-50. PMID 12374491 DOI: 10.1001/Archneur.59.10.1541 |
0.334 |
|
| 2002 |
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology. 51: 604-12. PMID 12112107 DOI: 10.1002/Ana.10191 |
0.349 |
|
| 2001 |
Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial Movement Disorders. 16: 135-139. PMID 11215574 DOI: 10.1002/1531-8257(200101)16:1<135::Aid-Mds1006>3.0.Co;2-Q |
0.356 |
|
| 1998 |
Kieburtz K, Frey K, Albin R, Marek K, Bates G, Aylward E, Guttman M, Rouleau G, Baehr M, Pahwa R, Lyons KE, Wilkinson SB, Kieltyka J, Koller WC, Bertoni JM, ... ... Oakes D, et al. Twelfth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Etiology, Pathogenesis, and Treatment of Huntington's Disease, Queen Elizabeth Hotel, Montreal, Canada, 18 October 1998 Movement Disorders. 13: 858-863. DOI: 10.1002/Mds.870130522 |
0.307 |
|
| 1997 |
LeWitt P, Oakes D, Cui L. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol Movement Disorders. 12: 183-189. PMID 9087976 DOI: 10.1002/Mds.870120208 |
0.36 |
|
| 1996 |
Penney JB, Oakes D, Shoulson I, Fahn S, Lang A, William Langston J, LeWitt P, Warren Olanow C, Tanner C, Kieburtz K. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa Annals of Neurology. 39: 37-45. PMID 8572664 DOI: 10.1002/Ana.410390107 |
0.352 |
|
| 1990 |
Oakes D, McDermott M, Eberly S, Plumb S, Watts A, Shoulson I. ·P-17 Investigator effects in a multicenter trial for parkinson's disease Controlled Clinical Trials. 11: 284. DOI: 10.1016/0197-2456(90)90116-J |
0.336 |
|
| 1989 |
Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A, Plumb S, Kurlan R. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Annals of Neurology. 25: 252-259. PMID 2524992 DOI: 10.1002/Ana.410250308 |
0.327 |
|
| 1986 |
Oakes D. Semiparametric inference in a model for association in bivanate survival data Biometrika. 73: 353-361. DOI: 10.1093/Biomet/73.2.353 |
0.301 |
|
| Show low-probability matches. |